Published date: July 30, 2021
BioPlus (CEO Jung Hyun-kyu), a company specializing in bio-material applications, announced on the 30th that it has been approved by the Korea Exchange for preliminary screening of KOSDAQ listing.
As a result, Bioplus will submit a securities declaration as soon as it prepares all the matters and push for a public offering process for IPO. The listed company was taken over by “Kiwoom Securities”.
Founded in 2003, BioPlus specializes in medical devices and bio-products based on polymeric biomaterials and has the world’s only platform technology, “MDM Tech,” in the application of hyaluronic acid (HA), a biomaterial. Products produced based on this core technology are excellent in viscosity, elasticity, safety, persistence, biocompatibility, and biodegradability.
Currently, its main products are Dermal Filler, anti-adhesive agents, joint tissue recovery materials, etc., and it is focusing its capabilities on developing new products such as bladder tissue recovery materials, bio-massage materials, and next-generation botulinum toxin to diversify its business portfolio.
By establishing a joint corporation in Hainan, China, and establishing beauty-molding complex platforms such as research institutes, production bases and medical institutions in China, the company plans to further increase overseas sales, including Hong Kong and Southeast Asia, and expand the company’s appearance and profitability.
“We will further accelerate R&D, facility investment, and overseas markets through KOSDAQ listing and maximize corporate value,” said CEO Jung Hyun-kyu of BioPlus. “We will grow as a global leader in bio-material applications and become a leading company in bio-industry.”
Meanwhile, BioPlus has continued to grow at an annual high rate of over 79% since its sales and marketing activities began in 2015, and has recorded an unrivaled operating profit rate of more than 50%.